Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

View all →   RSSRecent Releases
Jun 2, 2018 Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting
Jun 1, 2018 Celldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
May 10, 2018 Form 10-Q View HTML View PDF 430.4 KB Add to Briefcase
Mar 7, 2018 Form 10-K View HTML View PDF 1.6 MB Add to Briefcase
Add to Briefcase = add file to Briefcase